In the world of drug delivery, Rapidfilm®, AdhexPharma’s orodispersible film technology, is redefining how active pharmaceutical ingredients (APIs) are administered and absorbed. Designed for convenience, precision, and speed, Rapidfilm® provides a seamless therapeutic experience for patients while ensuring optimal drug absorption. But how exactly does it work in the gastrointestinal (GI) tract? Let’s break it down.
How Rapidfilm® Delivers APIs: From Mouth to Systemic Circulation.
When a Rapidfilm® is placed on the tongue, it begins to dissolve within seconds, releasing the API into the saliva. Unlike traditional tablets or capsules, no water or chewing is required. This makes Rapidfilm® ideal for patients with swallowing difficulties, such as children, the elderly, or those with dysphagia.
Examples of APIs commonly formulated in orodispersible films include:
The dissolved API is then swallowed along with saliva and enters the GI tract, where the absorption process begins.
After ingestion, the API passes through the esophagus into the stomach and small intestine. The small intestine plays a pivotal role in absorption due to:
Rapidfilm® ensures APIs are released in a bioavailable form, ready for efficient absorption.
Once absorbed, the API enters the portal vein and travels to the liver, where it undergoes metabolism. This first-pass effect can influence drug bioavailability.
After metabolism, the API is distributed via systemic circulation to the target tissues, delivering its therapeutic effect. Rapidfilm® ensures consistent and precise dosing, critical for drugs with narrow therapeutic windows like some well-known APIs for CNS diseases.
The Benefits of Rapidfilm® Technology
Patients often struggle with swallowing pills or managing complex medication regimens. Rapidfilm® simplifies administration, requiring no water, chewing, or effort - just place it on the tongue, and the rest happens naturally.
Most of the time, Rapidfilm® dissolves within seconds, significantly reducing the time it takes for APIs to begin acting compared to traditional oral dosage forms. Sometimes, the API still has to move through the small intestine. This is particularly beneficial for conditions requiring immediate relief, such as:
Each Rapidfilm® contains a carefully measured dose of the API, ensuring accuracy and minimizing the risk of under or overdosing.
Lightweight and discreet, Rapidfilm® fits effortlessly into patients’ lifestyles. Whether at home, work, or on the go, it offers a practical solution without compromising efficacy.
Rapidfilm® accommodates a wide range of APIs, including those with:
Rapidfilm®: Advancing GI Absorption for Better Therapeutics
AdhexPharma’s Rapidfilm® technology not only simplifies medication administration but also ensures efficient and reliable GI absorption. By leveraging cutting-edge formulation techniques, Rapidfilm® maximizes the therapeutic potential of APIs while addressing patient-centric needs.
Whether it’s for improving the bioavailability of sensitive APIs, offering faster relief for acute conditions, or enhancing the patient experience, Rapidfilm® is setting new standards in drug delivery.
If you're looking to bring a breakthrough product to market or enhance the life cycle of an existing drug, AdhexPharma’s Rapidfilm® technology offers the expertise and innovation you need.